Maastricht, the Netherlands, January 24, 2014 / B3C newswire / – PharmaCell B.V. a leading Contract Manufacturing Organization for Cellular Therapies and Regenerative Medicine in Europe, announced today that it has entered into an agreement with TiGenix N.V. to purchase its state-of-the-art cell therapy production facility at the Chemelot site in Sittard-Geleen, close to Maastricht (The Netherlands). TiGenix is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®.
TiGenix and PharmaCell have signed an agreement to purchase the shares of TiGenix B.V., which holds the manufacturing site, subject to certain closing conditions and intend to close the transaction in the coming months. PharmaCell will acquire the facility, including its qualified team of employees in Production, QC, QA and other functions. ChondroCelect® will continue to be manufactured at the facility as before under a long-term CMO agreement with PharmaCell.
In 2012, TiGenix’s state-of-the-art manufacturing facility in Sittard-Geleen, the Netherlands, successfully passed cGMP inspection by the Dutch authorities, and obtained approval from the European Medicines Agency for the production of ChondroCelect®, the company’s commercial cell therapy product for cartilage repair in the knee. Going forward, PharmaCell intends to produce other commercial and investigational cell therapy and regenerative medicine products at the site.
Alexander Vos, CEO of PharmaCell B.V. said: “The new partnership with TiGenix is a further step forward to strengthen our business in support of the development of the cell therapy industry in Europe. PharmaCell and TiGenix have created a collaborative business model for cell therapeutics in general and for ChondroCelect® in particular.”
PharmaCell is a leading European-based CMO active in the area of cell therapy and regenerative medicine. PharmaCell has experience in supporting Phase I through Phase III clinical trials and early commercial manufacturing in cell therapy in terms of manufacturing, QC, storage, in-outgoing logistics and product release through its in-house QPs. PharmaCell is exclusively focused on providing contract services in the area of human cell therapy. Its services also include process and assay-development to ensure GMP compliance, robustness and scalability of cell therapy manufacturing processes.
TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).
For more information:
Chief Executive Officer
+31 43 35 09910
Soenke Brunswieck, PhD
Director Business Development
+31 43 35 09910